Mafuta
Details were in the annual report not really sure how you can complain for not being bothered to read a document freely accessible on the company website?
Notice of Annual General Meeting
continued
NOTICE IS GIVEN that the Annual General Meeting (the âAGMâ) of Nuformix plc (the âCompanyâ) will be held at Orega, 70 Gracechurch Street, London, EC3V 0HR on 24 August 2021 at 10.00am and if thought fit, pass the following resolutions. Resolutions 1 to 10 will be proposed as ordinary resolutions and resolutions 11 to 13 will be proposed as special resolutions.
We are keen to welcome shareholders in person to our 2021 Annual General Meeting this year, particularly given the constraints we faced in 2020 due to the COVID-19 pandemic. At present, it is possible under guidelines to allow shareholders to attend the AGM and therefore we are proposing to welcome shareholders to attend the AGM within safety constraints and in accordance with government guidelines.
Shareholders who cannot attend the AGM should email any questions they have, or would normally raise during the course of the AGM to info@nuformix.com. We will endeavour to respond to all questions received by 10.00am on 18 August 2021 with the Q&A that will be published on the Company website soon after the AGM.
Given the constantly evolving nature of the COVID-19 situation, should circumstances change before the time of the AGM, we want to ensure that we are able to adapt arrangements, within safety constraints and in accordance with government guidelines. Should we have to change arrangements, we will issue a further communication via a Regulatory Information Service. As such, we strongly recommend shareholders monitor such communications, which can also be found on our website at: https://nuformix.com/news/.
Indicative value. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset could be ~ÂŁ50m. This future value would suggest the current fair value for Nuformix lies in the ÂŁ10m to ÂŁ20m range (1.7p to 3.4p/share).
Cash to 2023. Nuformix results show net cash of ÂŁ1.6m, giving a runway into late CY2022 based on our model. Allenbys view
But Pete from Barnet knows best!!
As previously disclosed, we are expecting important readouts on the progress with NXP002 and NXP004 later in 2021 and positive outcomes on these will trigger licensing discussions with key players. Should this be the case, we will engage expertise in business development to pick up these projects.
Even without any short term licensing income, the Company is funded through to the first inflection point for NXP002, to complete the research on NXP004, license NXP001 and to fund licensing discussions for a sufficient runway after getting data.
As a Board, we are committed to navigating the Company through the next six months and beyond to achieve the best outcomes for our investors.
Fully funded until end of 2022!! Get your fact right before making yourself look stupid!!
This was only from March
The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy.
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
We are awaiting data at end of year and awaiting global licensing agreement for another drug in pipeline which will generate income
Again get your facts correct before spouting bull sheet !!
I think you need a little break to help your brain recover!! So everyone on twitter is the enemy and out to steal everyoneâs money. Iâm sat ÂŁ60k down on nfx but not blaming anyone other than myself also I understand that shares go up and they go down eventually nfx will get back up I have the patience to wait whether 6months longer or 6 years not fussed
Ffx you are going crazy sat here posting every day shares go up shares go down!! Each day a new conspiracy or anyone dare say the slightest positive thing you accuse them of being a p and d crew or twitter trader - Grow up !! So what if people make a few quid here and there after all thatâs the game we are all playing!! Obviously if it kept going up after you bought you would have you but it didnât accept that!!!
âThey may be sat on it in order to give a positive boost just before they meet with shareholders without giving the P&D crews a chance to unravel any price boostâ
You do post some utter nonsense lol!!!
They will announce news when they have news!! Not sure why everyone buying cheaper than you has to be part of a âp and d crewâ
You do love a conspiracy theory donât you!!
Iqai tweet
Nice feedback received from a neurorad regarding features in the latest release of
@IQAI_IB
Software (IB Neuro) - "The PSR [percent signal recovery] maps look awesome and I love having them".
https://twitter.com/IQAI_IB/status/1425450157890588679
This is the reply I just received after registering
Thank you for registering with Investor Meet Company. Your email address is now verified. Use the search bar to find the companies that you wish to follow, and click Add to Meet.
You will now automatically be invited to all meetings NUFORMIX PLC host on the platform
The spaces in the diary are colour coded with these as the meeting options
RESULTS PRESENTATION CONFIRMED
RESULTS EXPECTED
CLOSED PERIOD / TOO SOON AFTER LAST MEETING
COMPANY DRIVEN MEETING CONFIRMED
DEMAND DRIVEN MEETING AVAILABLE
DEMAND DRIVEN MEETING CONFIRMED
ANNUAL GENERAL MEETING
Nfx is just showing potential results 20/12-26/12
Hope this helps
We'd like to welcome NUFORMIX PLC to Investor Meet Company!
Register NOW to make sure you're invited to NUFORMIX PLC's next LIVE investor presentation.
Click below to register now #NFX
https://twitter.com/InvestorMeetCo/status/1425382369750622208
More information out today in regards to pri acquiring vectura interesting comments about inhaled therapies
PMI's has the resources, commitment and patience to both advance Vectura's existing strategy, and also further it geographically and extend into the development of proprietary inhaled therapeutic products, alongside the existing CDMO business.
¡ PMI strongly supports and is aligned with Vectura's strategy of delivering drugs through inhalation using innovative technology that can effectively address many of today's unmet medical needs. The inhalation mode of administration allows for fast systemic absorption, potential fast onset of effect and a better safety profile due to the lower dose needed compared to standard of the care today.
¡ PMI's Beyond Nicotine strategy is built on two key growth areas - (1) inhaled therapeutics where we have already committed resources to our development pipeline of inhaled over-the-counter and prescription products and (2) developing and commercializing scientifically substantiated products and solutions that improve people's lives in areas like energy, sleep, calm and focus.
¡ PMI's significant expertise in aerosolization and inhalation, pre-clinical safety and clinical studies, as well as behavioral research and post-market studies forms the foundation of a science-based company that can continue to apply its skills to Life Sciences.
¡ PMI's commitment to transform itself requires an evolution into different industries with the application of our significant expertise in the inhalation space to address unmet medical and consumer needs by delivering products and solutions that improve people's lives.
¡ Operating Vectura as an autonomous business unit forming the backbone of PMI's inhaled therapeutics business, PMI will give Vectura the opportunity and tools to undertake the end-to-end development of inhalable drug-device combinations and will provide access to PMI's capabilities in areas such as pre-clinical safety, clinical development, regulatory affairs, drug safety, market access and global reach.
¡ PMI intends to increase the total level of expenditure on research and development that it believes will further benefit Vectura's differentiated technologies and development expertise for the delivery of complex inhaled therapeutics.
¡ Vectura can help bring the initial pipeline of "Beyond Nicotine" concepts that PMI has developed or acquired to market. This will exemplify PMI's strategy and give increased confidence in our transformation to the scientific community and to the public.
¡ In line with the UK's life sciences strategy and in keeping with the UK's position as a major scientific innovator, beyond supporting Vectura's growth, PMI believes these investments will support the scientific ecosystem in the UK for the longer term.
British bulls
Signal:BUY
Last Close:1.63
Change:+0.1500 Percent change+10.17%
Signal Update Our systemâs recommendation today is to BUY. The pattern finally received a confirmation because the prices crossed above the confirmation level which was at 1.53, and our valid average buying price stands now at 1.54. The previous SELL signal was issued on 23/06/2021, 40 days ago, when the stock price was 2.13. Since then NFX.L has fallen by -27.70%.Market Outlook Letâs jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.
licensing agreement with AstraZeneca worth a headline US$377mln and upfront milestone; and another preclinical licensing agreement with Abbvie and Morphic Therapeutics was also done with an undisclosed headline value, again with upfront milestones.
In NXP002, Nuformix has eschewed traditional drug development by creating a new form of the original drug, tranilast, which has a long history of safe use as an oral drug for allergies in Asia but with evidence that supports its potential in fibrosis, including IPF.
Nuformix has generated its own IP, repurposing an existing drug and giving it a potential new lease of life with significant commercial potential.
NXP002 is differentiated because it's a new form of tranilast and it will be formulated for delivery direct to the lungs by inhalation, a new route of administration for this drug.
There are two reasons why this change in route of administration is important.
The first is practical as it provides a targeted treatment with hopefully fewer side-effects.
The second is that by discovering novel forms of tranilast, Nuformix is able to generate IP and get patent protection from generics.
IPF itself is an area of high unmet medical need and an âorphanâ disease. Itâs a severe and progressive disease that affects the lungs, where dust, smoke, gastric reflux acid, genetic predisposition or infection leads to scarring known as fibrosis.
The prognosis is as bleak as some aggressive forms of cancer with an average survival time of three to five years.
While there are treatments, they tend only to be partially effective and have significant side-effects that cause some patients to stop treatment.
Because of the rarity of the disease, any new drugs that show signs of potential efficacy are likely to receive orphan drug designation.
This regulatory classification expedites the clinical trial process, reduces costs and extends the exclusivity period of the end product.
Taking the re-purposing route with Tranilast, rather than developing and testing a totally new molecule, compound or cell therapy, may also help shorten the timeline to market.
For example, a lot is already known about the safety and the way a drug such as Tranilast interacts with the body.
So, in this regard, there is also a greater probability of success, while the development costs are likely also to be lower than they would be with an unknown new therapy.
Utilising a technology known as cocrystallisation, Nuformix re-engineers a drugâs crystalline form by adding a molecule that improves it in a variety of ways â how well it can be absorbed by the body, for example.
Drug repurposing is a well-known strategy for enhancing the therapeutic and commercial value of marketed drugs:
⢠Greater probability of success compared to developing new drugs, due to the existing data, particularly safety, already generated on the marketed drug.
⢠Existence of data may also result in lower overall development costs and shorter development timelines.
⢠Commercial potential of these drugs may be enhanced by differentiation by way of formulation, route of administration or dose and gaining patent protection.
We aim to use our expertise in solid form science to discover and file patent applications on new solid forms to facilitate development of alternative formulations and delivery methods to repurpose marketed drugs into differentiated products for new indications.
Nuformix looks for three things in candidates suitable for their approach to reprofiling.
âIs the drug safe, does it have a problem our tech can improve and is there an underlying therapeutically innovative pharmacology with some level of validation in an area of unmet medical need.â
For example, using cocrystal technology can change key drug properties, such as solubility or dissolution rate, without changing the chemistry inside.
That means a drug can dissolve faster and to a greater extent so more of the drug gets into the patient, though solubility is just one of many problems an existing drug might face.
âMany properties hold drugs back from doing other things, but in certain cases we have an opportunity to change that.
âWhen we discover new drug cocrystals, we can patent these new substances and leverage their improved properties in new and unique products.â
âEvery drug cocrystal we discover, we breathe a new 20-year lifespan into products enabled by that substance.â
Drug reprofiling
Switching disease use is called drug reprofiling and means rather than starting from scratch when designing a new therapy, you take a treatment for disease A and reprofile it to treat disease B.
Because known drugs have usually been approved previously and their underlying chemistry is not changing, safety issues have been addressed, removing a major hurdle in drug development.
That leaves Nuformix just to prove that the new application passes muster against existing standard of care treatments.
âWe take our cocrystal-based products through development to proof-of-concept stage before seeking to out-license to a marketing partner,â
There has been a spate of preclinical deals, not least by the UKâs C4X Discovery, which has landed two separate partnerships â one with Indivior the other with Sanofi â worth a combined ÂŁ580mln in upfront, milestone and royalty payments. More relevant and in the area of fibrosis (IPF), AIM-listed Redx Pharma inked a
Itâs a load of bullsheet thatâs best to ignore although Nice to see all the multi ids on twitter pumping it!!
Hey âMissAnnaGreyâ or âReddit Trader Deluxeâ or âHive Imagingâ or âInvisible_Gregoryâ itâs blatantly obvious theyâre the same poster wouldnât be surprised if fandgle is another account of theirs
Iâm just as frustrated as others here but take reassurance from recent updates there is no point speculating things we canât control!
âAs previously disclosed, we are expecting important readouts on the progress with NXP002 and NXP004 later in 2021 and positive outcomes on these will trigger licensing discussions with key players. Should this be the case, we will engage expertise in business development to pick up these projects. Even without any short term licensing income, the Company is funded through to the first inflection point for NXP002, to complete the research on NXP004, license NXP001 and to fund licensing discussions for a sufficient runway after getting data. As a Board, we are committed to navigating the Company through the next six months and beyond to achieve the best outcomes for our investors.â
âLicensing deal under negotiation with Oxilio. A licensing deal is being finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment.â
Following successful completion of initial Phase I studies, our evaluation of the balance of investment and return directs us towards looking for regional or global licencing opportunities for NXP001. We will devote business development effort to this end and update the market as and when we are able to report progress.
Lots to look forward to !!! GLA